P Sirota

Summary

Country: Israel

Publications

  1. ncbi Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia
    P Sirota
    Abarbanel Mental Health Center, Bat Yam, Israel
    Am J Psychiatry 157:287-9. 2000
  2. ncbi Overproduction of neutrophil radical oxygen species correlates with negative symptoms in schizophrenic patients: parallel studies on neutrophil chemotaxis, superoxide production and bactericidal activity
    Pinkhas Sirota
    Y Abarbanel Mental Health Center, 15 Keren Kayemet Street, Bat Yam 59100, Israel
    Psychiatry Res 121:123-32. 2003
  3. ncbi Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients
    Pinkhas Sirota
    Y Abarbanel Mental Health Center, 15 Keren Kayemet Street, Bat Yam 59100, Israel
    Psychiatry Res 134:151-9. 2005
  4. ncbi Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia
    Pinkhas Sirota
    Abarbanel Mental Health Center, Bat Yam, Israel
    Hum Psychopharmacol 21:227-34. 2006
  5. ncbi Reduced anticardiolipin antibodies in first episode and chronic schizophrenia
    Pinkhas Sirota
    Abarbanel Mental Health Center, Bat Yam and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Psychiatry Res 144:211-6. 2006
  6. ncbi Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia
    Sherry Leonard
    Department of Psychiatry, Campus Box C 268 71, University of Colorado Health Sciences Center, 4200 E Ninth Ave, Denver, CO 80262, USA
    Arch Gen Psychiatry 59:1085-96. 2002
  7. ncbi Perseveration and over-switching in schizophrenia
    Herzel Yogev
    Department of Psychology, Tel Aviv University, Ramat Aviv 69978, Israel
    Schizophr Res 61:315-21. 2003
  8. ncbi Latent inhibition and overswitching in schizophrenia
    Herzel Yogev
    Tel Aviv University, Ramat Aviv, Israel
    Schizophr Bull 30:713-26. 2004

Detail Information

Publications8

  1. ncbi Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia
    P Sirota
    Abarbanel Mental Health Center, Bat Yam, Israel
    Am J Psychiatry 157:287-9. 2000
    ..The authors examined the efficacy, tolerability, and safety of ondansetron, a selective serotonin 3 receptor antagonist, in patients with tardive dyskinesia...
  2. ncbi Overproduction of neutrophil radical oxygen species correlates with negative symptoms in schizophrenic patients: parallel studies on neutrophil chemotaxis, superoxide production and bactericidal activity
    Pinkhas Sirota
    Y Abarbanel Mental Health Center, 15 Keren Kayemet Street, Bat Yam 59100, Israel
    Psychiatry Res 121:123-32. 2003
    ..Further studies are required to establish the role of oxidative stress in the ethiopathogenesis of schizophrenia...
  3. ncbi Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients
    Pinkhas Sirota
    Y Abarbanel Mental Health Center, 15 Keren Kayemet Street, Bat Yam 59100, Israel
    Psychiatry Res 134:151-9. 2005
    ..The results provide evidence for immune activation in some schizophrenic patients and suggest that medication differentially affects the production of sIL-2R(alpha) and IL-1ra...
  4. ncbi Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia
    Pinkhas Sirota
    Abarbanel Mental Health Center, Bat Yam, Israel
    Hum Psychopharmacol 21:227-34. 2006
    ..Although this is a small study with limited power, the results support the effectiveness of quetiapine and olanzapine in treating the negative symptoms of schizophrenia...
  5. ncbi Reduced anticardiolipin antibodies in first episode and chronic schizophrenia
    Pinkhas Sirota
    Abarbanel Mental Health Center, Bat Yam and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Psychiatry Res 144:211-6. 2006
    ..The higher background levels in schizophrenic patients may indicate a high level of antibodies to some serum component in schizophrenic patients that is still unclear and needs further elucidation...
  6. ncbi Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia
    Sherry Leonard
    Department of Psychiatry, Campus Box C 268 71, University of Colorado Health Sciences Center, 4200 E Ninth Ave, Denver, CO 80262, USA
    Arch Gen Psychiatry 59:1085-96. 2002
    ..This study presents DNA sequence analysis of the core promoter region for CHRNA7 in schizophrenic and control subjects...
  7. ncbi Perseveration and over-switching in schizophrenia
    Herzel Yogev
    Department of Psychology, Tel Aviv University, Ramat Aviv 69978, Israel
    Schizophr Res 61:315-21. 2003
    ..Over-switching is discussed as a specific symptom related to positive schizophrenia...
  8. ncbi Latent inhibition and overswitching in schizophrenia
    Herzel Yogev
    Tel Aviv University, Ramat Aviv, Israel
    Schizophr Bull 30:713-26. 2004
    ..These findings suggest that overswitching is a specific attention deficit in positive schizophrenia. We discuss the possibility that impaired LI is a consequence of overswitching and comment on the putative neurophysiology...